Seminars in Oncology
Volume 31, Issue 1 , Pages 68-82 , February 2004

Targeted cancer therapy and immunosuppression using radiolabeled monoclonal antibodies

  • Wolfgang A Bethge

      Affiliations

    • Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    • ,
  • Brenda M Sandmaier

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Brenda M. Sandmaier, MD, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N D1-100, Seattle, WA 98109-1024, USA
    • Department of Medicine, University of Washington, Seattle, WA, USA

References 

  1. Hericourt J, Richet C. “Physologie Pathologique”—de la serotherapie dans la traitement du cancer. C R Hebd Seanc Acad Sci. 1895;121:567–569
  2. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–497
  3. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998;91:1644–1652
  4. Tutt AL, French RR, Illidge TM, et al.  Monoclonal antibody therapy of B cell lymphoma (Signaling activity on tumor cells appears more important than recruitment of effectors). J Immunol. 1998;161:3176–3185
  5. Baselga J, Mendelsohn J. The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat. 1994;29:127–138
  6. Weiner LM. Monoclonal antibody therapy of cancer. Semin Oncol. 1999;26:43–51
  7. Grossbard ML, Press OW, Appelbaum FR, et al.  Monoclonal antibody-based therapies of leukemia and lymphoma. Blood. 1992;80:863–878
  8. Juweid M, Neumann R, Paik C, et al.  Micropharmacology of monoclonal antibodies in solid tumors (Direct experimental evidence for a binding site barrier). Cancer Res. 1992;52:5144–5153
  9. Fujimori K, Covell DG, Fletcher JE, et al.  A modeling analysis of monoclonal antibody percolation through tumors (A binding-site barrier). J Nucl Med. 1990;31:1191–1198
  10. Leunig M, Yuan F, Menger MD, et al.  Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. Cancer Res. 1992;52:6553–6560
  11. Mountain A, Adair JR. Engineering antibodies for therapy. Biotechnol Genet Eng Rev. 1992;10:1–142
  12. Kaminski MS, Zasadny KR, Francis IR, et al.  Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med. 1993;329:459–465
  13. Press OW, Eary JF, Appelbaum FR, et al.  Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993;329:1219–1224
  14. Press OW, Corcoran M, Subbiah K, et al.  A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood. 2001;98:2535–2543
  15. Zhang M, Yao Z, Garmestani K, et al.  Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. Blood. 2002;100:208–216
  16. Burke JM, Jurcic JG, Scheinberg DA. Radioimmunotherapy for acute leukemia. Cancer Control. 2002;9:106–113
  17. McDevitt MR, Sgouros G, Finn RD, et al.  Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med. 1998;25:1341–1351
  18. Macklis RM, Kinsey BM, Kassis AI, et al.  Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science. 1988;240:1024–1026
  19. Behr TM, Behe M, Lohr M, et al.  Therapeutic advantages of Auger electron over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies. Eur J Nucl Med. 2000;27:753–765
  20. Leigh BR, Burke PA, Hong AM, et al.  Preclinical evaluation of chimeric L6 antibody for the treatment of Kaposi’s sarcoma with radioimmunotherapy. Cancer Biother Radiopharm. 1999;14:113–119
  21. Syrigos KN, Deonarian DP, Epenetos AA. Use of monoclonal antibodies for the diagnosis and treatment of bladder cancer. Hybridoma. 1999;18:219–224
  22. Juweid ME, Hajjar G, Stein R, et al.  Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR. J Nucl Med. 2000;41:93–103
  23. Brady LW, Markoe AM, Woo DV, et al.  Iodine-125-labeled anti-epidermal growth factor receptor-425 in the treatment of glioblastoma multiforme. A pilot study. Front Radiat Ther Oncol. 1990;24:151–160
  24. Emrich JG, Brady LW, Quang TS, et al.  Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients (Ten-year synopsis of a novel treatment). Am J Clin Oncol. 2002;25:541–546
  25. Riva P, Franceschi G, Riva N, et al.  Role of nuclear medicine in the treatment of malignant gliomas (The locoregional radioimmunotherapy approach). Eur J Nucl Med. 2000;27:601–609
  26. Zalutsky MR, Zhao XG, Alston KL, et al.  High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use. J Nucl Med. 2001;42:1508–1515
  27. Paganelli G, Grana C, Chinol M, et al.  Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med. 1999;26:348–357
  28. Grana C, Chinol M, Robertson C, et al.  Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients (A pilot study). Br J Cancer. 2002;86:207–212
  29. Meredith RF, Khazaeli MB, Plott WE, et al.  Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer. J Nucl Med. 1995;36:2229–2233
  30. Welt S, Divgi CR, Kemeny N, et al.  Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol. 1994;12:1561–1571
  31. Behr TM, Memtsoudis S, Vougioukas V, et al.  Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting (Preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial). Anticancer Res. 1999;19:2427–2432
  32. Behr TM, Liersch T, Greiner-Bechert L, et al.  Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer. 2002;94:1373–1381
  33. Stewart JS, Hird V, Snook D, et al.  Intraperitoneal radioimmunotherapy for ovarian cancer (Pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies). Int J Radiat Oncol Biol Phys. 1989;16:405–413
  34. Jacobs AJ, Fer M, Su FM, et al.  A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma (Toxicity and clinical response). Obstet Gynecol. 1993;82:586–593
  35. Alvarez RD, Partridge EE, Khazaeli MB, et al.  Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49 (A phase I/II study). Gynecol Oncol. 1997;65:94–101
  36. Meredith RF, Partridge EE, Alvarez RD, et al.  Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J Nucl Med. 1996;37:1491–1496
  37. Nicholson S, Gooden CS, Hird V, et al.  Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer (A matched analysis). Oncol Rep. 1998;5:223–226
  38. Juweid M, Swayne LC, Sharkey RM, et al.  Prospects of radioimmunotherapy in epithelial ovarian cancer (Results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies). Gynecol Oncol. 1997;67:259–271
  39. Zanten-Przybysz I, Molthoff CF, Roos JC, et al.  Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer. J Nucl Med. 2000;41:1168–1176
  40. Alvarez RD, Huh WK, Khazaeli MB, et al.  A phase I study of combined modality (90)yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res. 2002;8:2806–2811
  41. Goldenberg DM, Nabi HA. Breast cancer imaging with radiolabeled antibodies. Semin Nucl Med. 1999;29:41–48
  42. Schrier DM, Stemmer SM, Johnson T, et al.  High-dose 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer (A phase I trial). Cancer Res. 1995;55(suppl):5921s–5924s
  43. Wong JY, Somlo G, Odom-Maryon T, et al.  Initial clinical experience evaluating yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer. Clin Cancer Res. 1999;5(suppl):3224s–3231s
  44. DeNardo SJ, O’Grady LF, Richman CM, et al.  Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. Anticancer Res. 1997;17:1745–1751
  45. Wilder RB, DeNardo GL, DeNardo SJ. Radioimmunotherapy (Recent results and future directions). J Clin Oncol. 1996;14:1383–1400
  46. Burke PA, DeNardo SJ, Miers LA, et al.  Combined modality radioimmunotherapy. Promise and peril. Cancer. 2002;94:1320–1331
  47. DeNardo SJ, Richman CM, Kukis DL, et al.  Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model (Development of a clinical protocol). Anticancer Res. 1998;18:4011–4018
  48. Meredith RF, Khazaeli MB, Macey DJ, et al.  Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin Cancer Res. 1999;5(suppl):3254s–3258s
  49. Deb N, Goris M, Trisler K, et al.  Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clin Cancer Res. 1996;2:1289–1297
  50. O’Donnell RT, DeNardo SJ, Yuan A, et al.  Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer. Clin Cancer Res. 2001;7:1561–1568
  51. Divgi CR, Bander NH, Scott AM, et al.  Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res. 1998;4:2729–2739
  52. Steffens MG, Boerman OC, de Mulder PH, et al.  Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res. 1999;5(suppl):3268s–3274s
  53. DeNardo SJ, DeNardo GL, O’Grady LF, et al.  Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies. Int J Biol Markers. 1987;2:49–53
  54. Press OW. Prospects for the management of non-Hodgkin’s lymphomas with monoclonal antibodies and immunoconjugates. Cancer J Sci Am. 1998;4(suppl):S19–S26
  55. DeNardo GL, DeNardo SJ, Lamborn KR, et al.  Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody. Cancer Biother Radiopharm. 1998;13:239–254
  56. DeNardo GL, DeNardo SJ, Goldstein DS, et al.  Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin’s lymphoma. J Clin Oncol. 1998;16:3246–3256
  57. O’Donnell RT, DeNardo GL, Kukis DL, et al.  A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin’s lymphoma. J Nucl Med. 1999;40:2014–2020
  58. Juweid M, Sharkey RM, Markowitz A, et al.  Treatment of non-Hodgkin’s lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res. 1995;55(suppl):5899s–5907s
  59. Vose J, Saleh M, Lister A, et al.  Iodine-131 anti-B1 antibody for non-Hodgkin’s lymphoma (NHL) (Overall clinical trial experience). Proc Am Soc Clin Oncol. 1998;17:10a; (abstr)
  60. Vose JM, Wahl RL, Saleh M, et al.  Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol. 2000;18:1316–1323
  61. Witzig TE, White CA, Wiseman GA, et al.  Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 1999;17:3793–3803
  62. Witzig TE, Flinn IW, Gordon LI, et al.  Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:3262–3269
  63. Witzig TE, Gordon LI, Cabanillas F, et al.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:2453–2463
  64. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002;43:693–713
  65. Liu SY, Eary JF, Petersdorf SH, et al.  Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol. 1998;16:3270–3278
  66. Press OW, Eary JF, Gooley T, et al.  A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000;96:2934–2942
  67. Gopal AK, Rajendran JG, Petersdorf SH, et al.  High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood. 2002;99:3158–3162
  68. Herpst JM, Klein JL, Leichner PK, et al.  Survival of patients with resistant Hodgkin’s disease after polyclonal yttrium 90-labeled antiferritin treatment. J Clin Oncol. 1995;13:2394–2400
  69. Vriesendorp HM, Quadri SM, Wyllie CT, et al.  Fractionated radiolabeled antiferritin therapy for patients with recurrent Hodgkin’s disease. Clin Cancer Res. 1999;5(suppl):3324s–3329s
  70. Ellis JH, Barber KA, Tutt A, et al.  Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. J Immunol. 1995;155:925–937
  71. Supiot S, Faivre-Chauvet A, Couturier O, et al.  Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma. Cancer. 2002;94:1202–1209
  72. Burton J, Mishina D, Cardillo T, et al.  Epithelial mucin-1 (MUC1) expression and MA5 anti-MUC1 monoclonal antibody targeting in multiple myeloma. Clin Cancer Res. 1999;5(suppl):3065s–3072s
  73. Treon SP, Pilarski LM, Belch AR, et al.  CD20-directed serotherapy in patients with multiple myeloma (Biologic considerations and therapeutic applications). J Immunother. 2002;25:72–81
  74. Giralt S, Champlin R, Goodman M, et al.  Preliminary results of a phase I/II study of multiple myeloma (MM) patients treated with 166-holmium-DOTMP in combination with high dose melphalan +/-total body irradiation (TBI) with autologous stem cell transplant. Blood. 2000;96:558a; (abstr)
  75. Griffin JD, Linch D, Sabbath K, et al.  A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res. 1984;8:521–534
  76. Appelbaum FR, Matthews DC, Eary JF, et al.  The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation. 1992;54:829–833
  77. Ruffner KL, Matthews DC. Current uses of monoclonal antibodies in the treatment of acute leukemia. Semin Oncol. 2000;27:531–539
  78. Schwartz MA, Lovett DR, Redner A, et al.  Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol. 1993;11:294–303
  79. Jurcic JG, Caron PC, Nikula TK, et al.  Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res. 1995;55(suppl):5908s–5910s
  80. Jurcic JG, DeBlasio T, Dumont L, et al.  Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res. 2000;6:372–380
  81. Waldmann TA, White JD, Carrasquillo JA, et al.  Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood. 1995;86:4063–4075
  82. van der Jagt RH, Badger CC, Appelbaum FR, et al.  Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model. Cancer Res. 1992;52:89–94
  83. Andres TL, Kadin ME. Immunologic markers in the differential diagnosis of small round cell tumors from lymphocytic lymphoma and leukemia. Am J Clin Pathol. 1983;79:546–552
  84. Caldwell CW, Patterson WP, Hakami N. Alterations of HLe-1 (T200) fluorescence intensity on acute lymphoblastic leukemia cells may relate to therapeutic outcome. Leuk Res. 1987;11:103–106
  85. Matthews DC, Appelbaum FR, Eary JF, et al.  Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood. 1999;94:1237–1247
  86. Bunjes D, Buchmann I, Duncker C, et al.  Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome (Results of a phase I-II study). Blood. 2001;98:565–572
  87. Huneke RB, Pippin CG, Squire RA, et al.  Effective alpha-particle-mediated radioimmunotherapy of murine leukemia. Cancer Res. 1992;52:5818–5820
  88. Hartmann F, Horak EM, Garmestani K, et al.  Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac. Cancer Res. 1994;54:4362–4370
  89. McDevitt MR, Ma D, Lai LT, et al.  Tumor therapy with targeted atomic nanogenerators. Science. 2001;294:1537–1540
  90. Abbas Rizvi SM, Sarkar S, Goozee G, et al.  Radioimmunoconjugates for targeted alpha therapy of malignant melanoma. Melanoma Res. 2000;10:281–289
  91. McDevitt MR, Finn RD, Ma D, et al.  Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use. J Nucl Med. 1999;40:1722–1727
  92. Jurcic JG, McDevitt MR, Sgouros G, et al.  Phase I trial of targeted alpha-particle therapy for myeloid leukemias with bismuth-213-HuM195 (anti-CD33). J Clin Oncol. 1999;18:7a; (abstr)
  93. Sgouros G, Ballangrud AM, Jurcic JG, et al.  Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody (213Bi-HuM195 (anti-CD33) in patients with leukemia). J Nucl Med. 1999;40:1935–1946
  94. Ruffner KL, Martin PJ, Hussell S, et al.  Immunosuppressive effects of 131I-anti-CD45 antibody in unsensitized and donor antigen-presensitized H2-matched, minor antigen-mismatched murine transplant models. Cancer Res. 2001;61:5126–5131
  95. Storb R, Yu C, Wagner JL, et al.  Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 1997;89:3048–3054
  96. McSweeney PA, Niederwieser D, Shizuru JA, et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies (Replacing high-dose cytotoxic therapy with graft-versus-tumor effects). Blood. 2001;97:3390–3400
  97. Wu C, Kobayashi H, Sun B, et al.  Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-CyDTPA. Bioorg Med Chem. 1997;5:1925–1934
  98. Sandmaier BM, Bethge WA, Wilbur DS, et al.  Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. Blood. 2002;100:318–326
  99. Bethge WA, Wilbur DS, Storb R, et al.  Selective T-cell ablation with bismuth-213 labeled anti-TCRαβ as nonmyeloablative conditioning for allogeneic canine marrow transplantation. Blood. 2003;101:5068–5075

☆ Supported in part by Grants No. HL36444, CA78902, and CA15704 awarded by the National Institutes of Health, Department of Health and Human Services, Bethesda, MD, and by a grant from the Gabrielle Rich Leukemia Foundation. W.A.B. was supported by a fellowship from Deutsche Krebshilfe, Dr. Mildred-Scheel-Stiftung für Krebsforschung.

PII: S0093-7754(03)00566-9

doi: 10.1053/j.seminoncol.2003.11.004

Seminars in Oncology
Volume 31, Issue 1 , Pages 68-82 , February 2004

Article Tools

* Image Usage & Resolution